Literature DB >> 12916913

Studies in formulation and pharmacotechnical evaluation of controlled release transdermal delivery system of bupropion.

Deepak Gondaliya1, Kilambi Pundarikakshudu.   

Abstract

The objective of the present study was to design and evaluate unilaminate transdermal adhesive matrix systems capable of diffusing bupropion base at a constant rate over an extended period of time as an alternative route of administration. Unilaminate transdermal adhesive matrices have been fabricated with different concentrations of Eudragit E as the adhesive and rate-controlling polymer. The in vitro release and epidermal flux through human cadaver skin were studied. The release of drug from the matrices obeyed zero order release kinetics (r2 = 0.9810 to 0.9960). The delivery rate of bupropion ranged from 10.5 mg to 31.4 mg per day from a 3.14 cm2 area of matrix. The relation between concentration of bupropion base in matrix and epidermal flux, concentration of drug in matrix, and epidermal adsorption of bupropion during diffusion follow hyperbolic fashion. Triethylcitrate (TEC) and dibutylphthalate (DBP) have no influence on the diffusion of bupropion through human cadaver skin when used as plasticizers. Incorporation of succinic acid in the adhesive matrix retarded diffusion due to the formation of rigid cross linking of the polymer, while propylene glycol and myristic acid, alone or in combination, significantly enhanced the flux of bupropion through human cadaver skin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12916913      PMCID: PMC2750299          DOI: 10.1208/pt040103

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  7 in total

1.  Transdermal oxymorphone formulation development and methods for evaluating flux and lag times for two skin permeation-enhancing vehicles.

Authors:  B J Aungst; J A Blake; N J Rogers; M A Hussain
Journal:  J Pharm Sci       Date:  1990-12       Impact factor: 3.534

Review 2.  Rate-control drug delivery systems: controlled release vs. sustained release.

Authors:  Y W Chien
Journal:  Med Prog Technol       Date:  1989

3.  Effect of topical vehicle composition on the in vitro release of fluocinolone acetonide and its acetate ester.

Authors:  B J Poulsen; E Young; V Coquilla; M Katz
Journal:  J Pharm Sci       Date:  1968-06       Impact factor: 3.534

4.  Increased skin permeability for lipophilic molecules.

Authors:  E R Cooper
Journal:  J Pharm Sci       Date:  1984-08       Impact factor: 3.534

5.  Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression.

Authors:  R A Sweet; B G Pollock; M Kirshner; B Wright; L P Altieri; C L DeVane
Journal:  J Clin Pharmacol       Date:  1995-09       Impact factor: 3.126

6.  Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder.

Authors:  L L Barrickman; P J Perry; A J Allen; S Kuperman; S V Arndt; K J Herrmann; E Schumacher
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1995-05       Impact factor: 8.829

7.  Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose.

Authors:  S C Laizure; C L DeVane; J T Stewart; C S Dommisse; A A Lai
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

  7 in total
  2 in total

1.  Development of mesophasic microreservoir-based transdermal drug delivery system of propranolol.

Authors:  L K Omray; S Kohli; A J Khopade; S Patil; Asmita Gajbhiye; G P Agrawal
Journal:  Indian J Pharm Sci       Date:  2008-09       Impact factor: 0.975

2.  Development of novel budesonide pellets based on CODES(TM) technology: In vitro/in vivo evaluation in induced colitis in rats.

Authors:  J Varshosaz; J Emami; N Tavakoli; M Minaiyan; N Rahmani; F Dorkoosh; P Mahzouni
Journal:  Daru       Date:  2011       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.